Bioventure FZ-LLC (“BV”) is a UAE-based biopharmaceutical company with a global network, focused on biotech and a wide range of pharmaceutical activities, delivering world-class solutions within the UAE and the Middle East.

BV specializes in biotech and generics commercialization, tech transfer and in/out-licensing activities. BV currently holds 2.5% equity stake in Alvotech and signed an agreement for an exclusive distribution and commercialization of Alvotech’s biosimilar portfolio across the Middle East and Africa. In addition, BV enjoys exclusive partnership and distribution rights regarding the sale of Adalvo targeted generic pharmaceuticals portfolio across the Middle East and North Africa region with continuous expansion plans on the way. The portfolio consists of 30 generic pharmaceuticals in the field of oncology, autoimmune and inflammation and blood disease.